Text Size
Santen Global

2022 IR News

RSS

IR News

Santen Announces Status of Share Buyback
Notice of Personnel Changes
Santen launches the dry-eye treatment DIQUAS® LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -
Santen Reports the 2nd Quarter Fiscal 2022 Consolidated Performance
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Santen Announces Share Buyback
Santen Strengthens Global Product Supply Base with Completion of Third Building on Site of Shiga Product Supply Center
Santen Publishes its Annual Integrated Report "Santen Report 2022"
Santen filing accepted by European Medicines Agency (EMA) for review of application for marketing authorization of the use of STN1013001 cationic emulsion of latanoprost 50?g/mL in glaucoma
Santen Announces Cancellation of Treasury Shares
Ophthalmic VEGF inhibitor Eylea® Solution for Intravitreal Injection 40 mg/mL obtains approval for ROP as sixth indication
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Corporate Governance Report
Notice of Personnel Change
Santen Announces Change of Representative Director of the Board (change in CEO)
Santen Announces Completion of Share Buyback
Santen Announces Status of Share Buyback
Santen Reports the 1st Quarter Fiscal 2022 Consolidated Performance
Santen Announces Status of Share Buyback
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen Announces Status of Share Buyback
Santen Announces Endorsement of Task Force on Climate-Related Financial Disclosures (TCFD)
Corporate Governance Report
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen receives manufacturing and marketing approval for the dry-eye treatment DIQUAS LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -
Santen and UBE announces U.S. Food and Drug Administration accepts resubmission of NDA for STN1011700 / DE-117 (omidenepag isopropyl) for treating glaucoma and ocular hypertension
Santen Announces Status of Share Buyback
Santen and ActualEyes start registering patients to participate in Phase II clinical trial (Phase IIa / PoC study, PHANTOM study) for Fuchs endothelial corneal dystrophy
Santen Announces Change of Representative Director of the Board and Board of Director and Corporate Auditor Nominations
Santen Received the Approval of Verkazia (Ciclosporin Eye Drops (III)), Providing New Solutions for Severe Vernal Keratoconjunctivitis in China
Santen Announces Share Buyback
Notice on the Formulation of a Share Buyback Policy
Notice regarding Cancellation of 'Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year'
Santen Reports Fiscal 2021 Consolidated Performance
Santen's Verkazia (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States
Santen Announces Change of Major Shareholder
Santen Announces Change of Representative Director of the Board
Santen to Present Latest Data on Omidenepag Isopropyl at AGS 2022
Santen Wins Award for Excellence at the "Nikkei Integrated Report Award 2021"
Santen Receives Marketing Approval in Japan for "PRESERFLO MicroShunt Glaucoma Drainage System Core Kit" to Treat Glaucoma
Reinventing of Our Leadership Team to Shape the Future of Santen
Santen certified as Digital Transformation Business Operator by Ministry of Economy, Trade and Industry
Santen Reports the 3rd Quarter Fiscal 2021 Consolidated Performance
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved